Phenotypic antimicrobial susceptibility testing of Chlamydia trachomatis isolates from patients with persistent or successfully treated infections
Open Access
- 30 November 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 73 (3) , 680-686
Abstract
Antimicrobial susceptibility data for Chlamydia trachomatis are lacking. Methodologies for susceptibility testing in C. trachomatis are not well-defined, standardized or performed routinely owing to its intracellular growth requirements. We sought to develop an assay for the in vitro susceptibility testing of C. trachomatis isolates from two patient cohorts with different clinical outcomes. Twenty-four clinical isolates (11 from persistently infected and 13 from successfully treated patients) were overlaid with media containing two-fold serial dilutions of azithromycin or doxycycline. After incubation, aliquots were removed from the stock inoculum (SI) and each antimicrobial concentration for total RNA extraction, complementary DNA generation and real-time PCR. The MIC was defined as the lowest antimicrobial concentration where a 95% reduction in transcription was evident in comparison with the SI for each isolate. MICs of azithromycin were comparable for isolates from the two patient groups (82% ≤ 0.25 mg/L for persistently infected and 100% ≤ 0.25 mg/L for successfully treated patients). Doxycycline MICs were at least two-fold lower for isolates from the successfully treated patients (53.9% ≤ 0.064 mg/L) than for the persistently infected patients (100% ≥ 0.125 mg/L) (P = 0.006, Fisher’s exact test). Overall, 96% of isolates gave reproducible MICs when re-tested. A reproducible assay was developed for antimicrobial susceptibility testing of C. trachomatis. MICs of azithromycin were generally comparable for the two different patient groups. MICs of doxycycline were significantly higher in the persistently infected patients. However, interpretation of elevated MICs in C. trachomatis is extremely challenging in the absence of breakpoints, or wild-type and treatment failure MIC distribution data.Keywords
Funding Information
- Medical Research Council (G0601663)
This publication has 31 references indexed in Scilit:
- Higher organism load associated with failure of azithromycin to treat rectal chlamydiaEpidemiology and Infection, 2016
- Azithromycin versus Doxycycline for UrogenitalChlamydia trachomatisInfectionNew England Journal of Medicine, 2015
- Treatment challenges for urogenital and anorectal Chlamydia trachomatisBMC Infectious Diseases, 2015
- Azithromycin Versus Doxycycline for the Treatment of Genital Chlamydia Infection: A Meta-analysis of Randomized Controlled TrialsClinical Infectious Diseases, 2014
- Detection of Anorectal and Cervicovaginal Chlamydia Trachomatis Infections following Azithromycin Treatment: Prospective Cohort Study with Multiple Time-Sequential Measures of rRNA, DNA, Quantitative Load and SymptomsPLOS ONE, 2013
- Azithromycin antimicrobial resistance and genitalChlamydia trachomatisinfection: duration of therapy may be the key to improving efficacySexually Transmitted Infections, 2012
- Lack of mutation in macrolide resistance genes in Chlamydia trachomatis clinical isolates with decreased susceptibility to azithromycinInternational Journal of Antimicrobial Agents, 2011
- Decreased Susceptibility to Azithromycin and Doxycycline in Clinical Isolates of Chlamydia trachomatis Obtained from Recurrently Infected Female Patients in IndiaChemotherapy, 2010
- Mutations in a 23S rRNA Gene of Chlamydia trachomatis Associated with Resistance to MacrolidesAntimicrobial Agents and Chemotherapy, 2004
- Multiple Drug–ResistantChlamydia trachomatisAssociated with Clinical Treatment FailureThe Journal of Infectious Diseases, 2000